Anavex Life Sciences Corp (AVXL)

[falconer66a]

Won’t work; not a med-school professor.

–perhaps you (or anyone else here with med. writing expertise)-could (should) enlighten NYT staff-what a great story is unfolding here–

Good Idea. Yes, the New York Times should be made aware of the developing, evidence-based Anavex story. But, with the Times, in this case, should is not an operating word.

The Times gets their information for articles, especially medical ones, from recognized “experts,” meaning, top-line medical school faculty. Certainly, people writing about Anavex on some web-based stock investors message board, regardless of their actual scientific knowledge, are utterly dismissed. What could anyone here really know? The med-school faculty know neurology; what works, what can’t. For them, blarcamesine is too good to be true. Violates everything they authoritatively know about neuron biochemistry.

After all, it is known that Alzheimer’s is caused by accumulations of beta-amyloids and tau tangles. Blarcamesine doesn’t bind to either, can’t possibly have any therapeutic effects on these waste proteins.

Medicine (and obsequious news writers) generally resist “new science.” (Check the story of "germs" causing disease. Took many decades: https://en.wikipedia.org/wiki/Ignaz_Semmelweis). There is “established knowledge,” telling how things really are. Proffered new ideas on how organic systems might actually work, especially neurons, are soundly rejected. “Nope, that can’t possibly be, because....”

The Times writers are smart and educated. Like the med school professors, they know the “real science.” Pointing out to them the preclinical data on blarcamesine will be pointless. “Sorry, all of that will have to be confirmed by broad, large-scale double-blind clinical studies. Right now, there are none of those.”

So, NYT science writers will say nothing positive about blarcamesine until the big trial results appear, probably in 2022 and 23. I won’t be wasting any of my time or technical writing skills on the otherwise good NYT writers, unless they’d invite to learn of my perspectives. I’ll keep checking my emails each day.